Pds biotech announces participation in h.c. wainwright bioconnect 2021 virtual conference

Florham park, n.j., jan. 05, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced that chief executive officer dr. frank bedu-addo will be presenting at h.c. wainwright's bioconnect virtual conference. pds biotech's presentation will be available on-demand beginning january 11, 2021 at 6:00 am et and can be accessed online here.
PDSB Ratings Summary
PDSB Quant Ranking